Assistance Publique—Hôpitaux de Paris (APHP) is the largest hospital system in Europe and one of the largest worldwide. Linked with the University of Paris and its seven colleges of medicine, APHP commenced an observational cohort study of patients treated in their hospital for SARS-2-CoV-2, the virus behind COVID-19. Investigators at APHP seek to better understand how to clinically, biologically and radiologically characterize the SARS-CoV-2 infections. The team is also collecting therapeutic strategies implemented, their possible toxicity land the evolution of the patients.
As APHP reported, the COVID-19 has wreaked havoc across the world affecting 4.3 million worldwide and counting. Infection with the virus of the coronavirus family triggers a broad clinical spectrum, the main manifestation of which is an influenza-like condition associated with a pattern of severe hypoxemia pneumonia, and in some cases fatal. APHP acknowledges little is known about this pathology, so the team embarked on this observational cohort study.
This study will study 500 in an observational cohort study. Titled “Observational Cohort of COVID-19 Patients at Raymond Poincare.” The study commenced April 2020 and runs through May 2020. As little is known about this novel coronavirus, investigators at APHP seek to better understand how to clinically, biologically and radiologically characterize the SARS-CoV-2 infections. The team is also collecting therapeutic strategies implemented, their possible toxicity land the evolution of the patients. The study takes place at APHP’s Raymond PoinCaré Hospital.
As much is unknown about SARS-CoV-2 many questions arise as to how to manage the care for these patients. What types of molecules should be introduced and at what point in the history of the disease? Some of these molecules, such as Lopinavir/Ritonavir combinations and the Hydroxychloroquine/Azithromycin combination, are not free of complications, particularly cardiac complications requiring close monitoring by ECGs and repeated dosing, the effectiveness of which is not yet been clearly demonstrated. Hence, in order to better understand the infection, this sponsor has set up and is conducting a cohort of patients treated for COVID-19 infection in their site.
Europe’s largest hospital, system—and one of the largest in the world—it provides health care, teaching, research, prevention, education, emergency medical services in 52 branches of medicine. The hospital employs more than 90,000 people (including 15,800 physicians) in 44 hospitals and receives over 5.8 million patients annually.
Raymond Poincare University Hospital is a hospital of the APHP and a teaching hospital of Versailles Saint-Quentin-en-Yvelines University. The hospital was built between 1932 and 1936 and was named after a French. In the 1950s the hospital specialized in the rehabilitation of polio sufferers (the disease was then widespread, include in France).
Simon Bessis, MD, Principal Investigator, Infectious Disease Department, Raymond PoinCaré Hospital, APHP
Aurelien Dinh, MD, Study Director, Infectious Diseases Department, Raymond PoinCaré Hospital, APHP
Call to Action: Interested in connecting with this team? Lets TrialSite News know and the connection can be made on your behalf.